MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Clovis Oncology Company Profile (NASDAQ:CLVS)

Consensus Ratings for Clovis Oncology (NASDAQ:CLVS) (?)
Ratings Breakdown: 6 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $32.11 (113.22% upside)

Analysts' Ratings History for Clovis Oncology (NASDAQ:CLVS)
Show:
DateFirmActionRatingPrice TargetActions
6/29/2016Piper JaffrayReiterated RatingHold$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/8/2016Credit SuisseReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/9/2016WallachBeth CapitalLower Price TargetHold$30.00 -> $22.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2016MizuhoReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2016Janney Montgomery ScottReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/13/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$42.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/12/2016Stifel NicolausReiterated RatingBuy$30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/28/2016Leerink SwannBoost Price TargetOutperform$104.00 -> $110.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Goldman SachsLower Price Target$23.00 -> $19.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2015Citigroup Inc.Boost Price TargetNeutral$60.00 -> $85.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/30/2014 forward)
Earnings History for Clovis Oncology (NASDAQ:CLVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/5/2016Q116($2.39)($2.17)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($2.44)($3.12)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($2.07)($2.62)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($1.99)($2.10)$1.17 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($1.82)($1.86)$13.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2015Q414($1.30)($1.62)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014Q314($1.07)($1.17)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.96)($1.03)$13.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q114($0.85)($0.91)$13.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2014Q4($0.78)($0.92)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/31/2013Q313($0.68)($0.68)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q2 2013($0.65)($0.72)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2013Q1 2013($0.60)($0.60)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Clovis Oncology (NASDAQ:CLVS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Clovis Oncology (NASDAQ:CLVS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/2/2015Erle T. MastCFOSell3,000$105.56$316,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/28/2015Lindsey RolfeinsiderSell4,000$98.02$392,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015Gillian C Ivers-ReadInsiderSell3,000$91.91$275,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Lindsey RolfeinsiderSell4,000$93.04$372,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Erle T. MastCFOSell3,000$90.22$270,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Gillian C Ivers-ReadInsiderSell3,000$112.56$337,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Erle T. MastCFOSell3,000$79.51$238,530.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Erle T MastCFOSell3,000$85.70$257,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Erle T MastCFOSell3,000$88.78$266,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015M James BarrettDirectorSell2,424$92.43$224,050.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015Erle T MastCFOSell3,000$71.25$213,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Erle T MastCFOSell9,000$78.84$709,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/5/2015James C BlairDirectorSell8,528$77.70$662,625.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/16/2015Steven L HoerterInsiderSell10,000$67.00$670,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2013Erle MastCFOSell50,000$52.78$2,639,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/5/2013Thorlef SpickschenDirectorSell9,000$56.10$504,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013Andrew R AllenInsiderSell22,594$68.54$1,548,592.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2013M James BarrettDirectorSell2,483$70.80$175,796.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2013Parters Vii L P DomainMajor ShareholderSell159,192$64.58$10,280,619.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2013Steven L HoerterInsiderSell10,000$73.06$730,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/6/2013Parters Vii L P DomainMajor ShareholderSell250,000$24.59$6,147,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/16/2012Edward J MckinleyDirectorBuy9,701$15.50$150,365.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Clovis Oncology (NASDAQ:CLVS)
DateHeadline
06/29/16 04:46 PMWhy Tesaro Inc (TSRO), Clovis Oncology Inc (CLVS) and Twilio Inc (TWLO) Are 3 of Today’s Best Stocks - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips It was a good day for the stock market, but TSRO, CLVS and TWLO managed to stand out from the pack. The post Why Tesaro Inc (TSRO), Clovis Oncology Inc (CLVS) and Twilio Inc (TWLO) Are 3 of Today’s Best Stocks appeared first on InvestorPlace.
06/29/16 03:14 PMClovis Higher In Sympathy With Tesaro
06/29/16 02:00 PMWhat's Causing Clovis Oncology Shares to Skyrocket Today? - A late-stage trial win for Tesaro may increase the chances that Clovis Oncology's similar drug will pan out, too.
06/29/16 11:20 AMWatching Stock Volatility for: Clovis Oncology, Inc. (NASDAQ:CLVS) - Engelwood Daily
06/29/16 11:20 AMClovis Oncology Inc. (CLVS) Jumps 6.78% on June 28 - Equities.com
06/29/16 10:49 AMHere’s Why These Five Stocks Are On the Move on Wednesday -
06/29/16 10:06 AMThese 15 Biotech Companies Could Be Takeover Targets -
06/29/16 08:45 AMClovis Oncology gets a bump from TESARO's success; shares up 17% premarket -
06/28/16 08:09 AMClovis Oncology, Inc. (CLVS) Trades at 52-Week Low - Finance Daily
06/28/16 08:09 AMClovis Oncology, Inc. (NASDAQ:CLVS) Broker Price Targets For The Coming Week - Fiscal Standard
06/23/16 08:04 AM5 Reasons to Hate Biotech Stocks -
06/20/16 02:21 PMSexy vs. Boring: Who’s Winning? - [ETFguide] - Higher investment risk leads to higher investment returns, right? It’s a Wall Street axiom that we’ve heard so many times it’s become ingrained in us. But conventional wisdom and reality have the peculiar ...
06/19/16 03:05 PMThis Weeks Broker Views For Clovis Oncology, Inc. (NASDAQ:CLVS) - Fiscal Standard
06/12/16 11:02 AMClovis Oncology files $200M shelf registration
06/11/16 03:22 PMEarnings Report: Clovis Oncology, Inc. (NASDAQ:CLVS), InvenSense, Inc. (NYSE:INVN) - Beacon Chronicle
06/10/16 07:32 AMCLOVIS ONCOLOGY, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/10/16 06:37 AMBRIEF-Clovis Oncology Inc files for mixed shelf of up to $200 mln - * Clovis Oncology Inc files for mixed shelf of up to $200 million Source text: http://1.usa.gov/1XdI04i Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)
06/09/16 09:19 AMYesterday's Consideration Movers: Neovasc Inc. (NASDAQ:NVCN) , Clovis Oncology, Inc. (NASDAQ:CLVS) - Street Updates
06/09/16 09:19 AMClovis Oncology Inc. (CLVS) Drops 5.48% on June 07 - Equities.com
06/07/16 08:54 PMClovis Oncology Inc. (CLVS) Jumps 6.38% on June 06 - Equities.com
06/06/16 03:08 PMAnalysts: Clovis Oncology, Inc. (NASDAQ:CLVS) stock is worth $17.5 - iStreetWire
06/06/16 03:08 PMCompany Update (NASDAQ:CLVS): Clovis Oncology Inc Presents Data from Phase 2 Studies of Rucaparib in ... - Smarter Analyst
06/06/16 07:48 AMClovis Oncology Presents Data from Phase 2 Studies of Rucaparib in Advanced Ovarian Cancer and Pancreatic Cancer at 2016 ASCO Annual Meeting - [at noodls] - BOULDER, Colo.--(BUSINESS WIRE)--Jun. 6, 2016-- Clovis Oncology (NASDAQ:CLVS) announced updated phase 2 results from Part 1 of the ongoing ARIEL2 study in patients with advanced ovarian cancer as well ...
06/05/16 11:05 AMNext Weeks Broker Price Targets For Clovis Oncology, Inc. (NASDAQ:CLVS) - Share Trading News
06/03/16 10:38 AMClovis Oncology, Inc. (NASDAQ:CLVS) Stock Update & Estimates - Stock Tick Tock
06/02/16 08:06 PMClovis Oncology Inc (NASDAQ:CLVS) Receives Consensus Recommendation of “Hold” from Analysts - Let Me Know About This - Clovis Oncology Inc (NASDAQ:CLVS) Receives Consensus Recommendation of “Hold” from AnalystsLet Me Know About ThisClovis Oncology logo Shares of Clovis Oncology Inc (NASDAQ:CLVS) have received a consensus rating of “Hold” from the eleven ratings firms that are currently covering the stock. Six analysts have rated the stock with a hold rating and four have issued a ...
06/02/16 12:01 PMStock's Move to Focus: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) , Clovis Oncology, Inc. (NASDAQ:CLVS) - Street Updates - Stock's Move to Focus: Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) , Clovis Oncology, Inc. (NASDAQ:CLVS)Street UpdatesOn 6/1/2016, Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) highlighted downward shift of -0.50% or -0.03 points to $5.98. The company traded a volume of 1.23 million shares under average volume of 1.7 million shares. Trailing twelve month period, the ...and more »
06/01/16 04:04 PMClovis Oncology, Inc. :CLVS-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
06/01/16 10:24 AMTrade sees ceiling in Clovis Oncology -
05/31/16 09:00 PMFEI Company (NASDAQ:FEIC) soared 14.33%: Clovis Oncology, Inc. (NASDAQ:CLVS), Imprimis Pharmaceuticals, Inc ... - KC Register - FEI Company (NASDAQ:FEIC) soared 14.33%: Clovis Oncology, Inc. (NASDAQ:CLVS), Imprimis Pharmaceuticals, Inc ...KC RegisterClovis Oncology, Inc. (NASDAQ:CLVS) announced its presence at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, where it will share updated results from clinical studies of rucaparib. ASCO will take place June 3-7, 2016 in Chicago.and more »
05/31/16 10:24 AMStock Review and Earnings Check on Clovis Oncology, Inc. (NASDAQ:CLVS) - HNN - Stock Review and Earnings Check on Clovis Oncology, Inc. (NASDAQ:CLVS)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Clovis Oncology, Inc.and more »
05/31/16 10:24 AMHealthcare Movers to Observe: Brookdale Senior Living Inc. (NYSE:BKD) , Clovis Oncology, Inc. (NASDAQ:CLVS) - Is stories - Healthcare Movers to Observe: Brookdale Senior Living Inc. (NYSE:BKD) , Clovis Oncology, Inc. (NASDAQ:CLVS)Is storiesBrookdale Senior Living Inc. (NYSE:BKD) decreased -0.99% to $18.00 while traded 3.98 million shares on 5/27/2016. The stock price negotiated for value between $17.87 to $18.35 in recent trading session. During the past 52 weeks, the stock's price ...and more »
05/30/16 10:46 PMClovis Oncology Inc (CLVS) Receives “Hold” Rating from Piper Jaffray - Let Me Know About This - Clovis Oncology Inc (CLVS) Receives “Hold” Rating from Piper JaffrayLet Me Know About ThisClovis Oncology logo Clovis Oncology Inc (NASDAQ:CLVS)'s stock had its “hold” rating reissued by stock analysts at Piper Jaffray in a report released on Sunday. A number of hedge funds and institutional investors have recently added to or reduced their ...
05/27/16 11:56 AMHealthcare Stocks in Target: Brookdale Senior Living Inc. (NYSE:BKD) , Clovis Oncology, Inc. (NASDAQ:CLVS) - Is stories - Is storiesHealthcare Stocks in Target: Brookdale Senior Living Inc. (NYSE:BKD) , Clovis Oncology, Inc. (NASDAQ:CLVS)Is storiesBrookdale Senior Living Inc. (NYSE:BKD) decreased -2.99% to $18.18 while traded 3.73 million shares on 5/26/2016. The stock price negotiated for value between $18.16 to $18.92 in recent trading session. During the past 52 weeks, the stock's price ...and more »
05/27/16 11:56 AMClovis Oncology, Inc. (NASDAQ:CLVS) Impact Score At 75 - Stocks Daily - Clovis Oncology, Inc. (NASDAQ:CLVS) Impact Score At 75Stocks DailyAlpha One explored various online articles released on Clovis Oncology, Inc. (NASDAQ:CLVS), and it set a daily sentiment score of -0.203 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the ...and more »
05/27/16 11:56 AMDon't Miss This Stock: Clovis Oncology Inc (NASDAQ:CLVS) - The Point Review - The Point ReviewDon't Miss This Stock: Clovis Oncology Inc (NASDAQ:CLVS)The Point ReviewShare of Clovis Oncology Inc (NASDAQ:CLVS) traded on 3.06 percent above secure line at 3:37PM EDT in order to take the company's stock at the price of $16.49. At the time of writing the stock exchanged hands 974,287 shares versus average trading ...Earnings Estimates Highlights: Clovis Oncology, Inc. (NASDAQ:CLVS)CWRU ObserverClovis Oncology Inc (CLVS) Downgraded to "Buy" at Vetr Inc.Community Financial News2 Sizzling Hot Biotechnology Stocks: Clovis Oncology (CLVS), Arena Pharmaceuticals (ARNA)ZergwatchCCH Daily News -The Post -WsNews 4investorsall 8 news articles »
05/26/16 11:03 AMBiotech Movers: Boston Scientific Corporation (NYSE:BSX) , Clovis Oncology, Inc. (NASDAQ:CLVS) - Is stories - Is storiesBiotech Movers: Boston Scientific Corporation (NYSE:BSX) , Clovis Oncology, Inc. (NASDAQ:CLVS)Is storiesShares of Clovis Oncology, Inc. (NASDAQ:CLVS) climbed +4.49% and ended at $15.58 greater than previous closing price of $14.91. The total 1.4 million shares were bought and sold throughout the most recent trading session less than average volume of ...and more »
05/25/16 04:43 PMKyle Bass Purchases Stake in Clovis Oncology - During the first quarter guru Kyle Bass (Trades, Portfolio) purchased 100,000 shares of Clovis Oncology Inc. (NASDAQ:CLVS). Clovis Oncology is a biopharmaceutical company that is headquartered in Boulder, Colorado. The company focuses on acquiring ...
05/24/16 08:24 AMEarnings Review and Stock Rundown for Clovis Oncology, Inc. (NASDAQ:CLVS) - Wall Street Hints and News - Earnings Review and Stock Rundown for Clovis Oncology, Inc. (NASDAQ:CLVS)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting Clovis Oncology, Inc. (NASDAQ:CLVS) to ...and more »
05/23/16 09:35 AMActive Stocks: Weatherford International plc (NYSE:WFT), Clovis Oncology, Inc. (NASDAQ:CLVS), Bank of America ... - KC Register - Active Stocks: Weatherford International plc (NYSE:WFT), Clovis Oncology, Inc. (NASDAQ:CLVS), Bank of America ...KC RegisterClovis Oncology, Inc. (NASDAQ:CLVS) announced its presence at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, where it will share updated results from clinical studies of rucaparib. ASCO will take place June 3-7, 2016 in Chicago.and more »
05/23/16 09:35 AMTraders Focused Stocks: Cesca Therapeutics Inc. (NASDAQ:KOOL) , Clovis Oncology, Inc. (NASDAQ:CLVS) - Street Updates - Traders Focused Stocks: Cesca Therapeutics Inc. (NASDAQ:KOOL) , Clovis Oncology, Inc. (NASDAQ:CLVS)Street UpdatesOn 5/20/2016, Cesca Therapeutics Inc. (NASDAQ:KOOL) ended trading session lower at $3.14 with -13.02%. The company traded a volume of 1.33 million shares as comparison to average volume of 165.31 thousand shares. During the 52 –week period, the ...and more »
05/20/16 09:51 PMActive Stocks' Revenge with Bears- Amazon.com (NASDAQ:AMZN), Clovis Oncology (NASDAQ:CLVS), Abraxas ... - Seneca Globe - Active Stocks' Revenge with Bears- Amazon.com (NASDAQ:AMZN), Clovis Oncology (NASDAQ:CLVS), Abraxas ...Seneca GlobeShares of Amazon.com, Inc. (NASDAQ:AMZN) raised 0.15% to finish at $698.52 in previous trading session. Amazon (AMZN) reported that its India unit forged a alliance with Development Commissioner Handloom of the Union Ministry of Textiles under which ...and more »
05/20/16 09:51 PMClovis Oncology, Inc. (NASDAQ:CLVS) One-Year Price Target Estimate At $17.50 - Investor Newswire - Clovis Oncology, Inc. (NASDAQ:CLVS) One-Year Price Target Estimate At $17.50Investor NewswireThe 52-week price target of Clovis Oncology, Inc. (NASDAQ:CLVS) is set at $17.50 after First Call completed its market based survey. It has estimated EPS of $-1.98 for approaching quarter and $-7.98 for ongoing year. The EPS estimate for next year is ...Is it Time to Cash in Profits on Clovis Oncology, Inc. (NASDAQ:CLVS)Franklin IndependentMorning Alert: The Gap, (NYSE:GPS), First Federal of Northern Michigan Bancorp, (NASDAQ:FFNM), Arthur J ...Benchmark Monitorall 5 news articles »
05/20/16 04:45 PMClovis Oncology Inc. (CLVS) Jumps 6.23% on May 20 - Equities.com - Clovis Oncology Inc. (CLVS) Jumps 6.23% on May 20Equities.comClovis Oncology Inc. (CLVS) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 6.23% to $14.50, representing a gain of $0.85 per share. Some 904,285 shares traded hands on 6,868 trades, compared with an average ...and more »
05/19/16 03:52 PMClovis Oncology Announces Data Presentations at 2016 ASCO Annual Meeting - [at noodls] - New rucaparib data to be highlighted in poster presentations Rolling New Drug Application (NDA) submission for rucaparib for the treatment of patients with advanced ovarian cancer expected to complete ...
05/19/16 03:41 PM4:41 pm Clovis Oncology to present new rucaparib data at ASCO -
05/18/16 04:45 PMClovis Oncology Inc. (CLVS) Jumps 7.59% on May 18 - Equities.com - Clovis Oncology Inc. (CLVS) Jumps 7.59% on May 18Equities.comClovis Oncology Inc. (CLVS) was among the biggest gainers on the Russell 2000 for Wednesday May 18 as the stock popped 7.59% to $13.75, representing a gain of $0.97 per share. Some 764,326 shares traded hands on 5,766 trades, compared with an ...and more »
05/18/16 12:04 PMCLOVIS ONCOLOGY, INC. Financials -
05/17/16 04:38 PMRevenue Update on Clovis Oncology Inc(NASDAQ:CLVS) - Trade Calls - Revenue Update on Clovis Oncology Inc(NASDAQ:CLVS)Trade CallsClovis Oncology Inc(NASDAQ:CLVS) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 5, 2016. Earnings per share were $-2.17. Analysts had estimated an EPS of $-2.39. In a different note, On Apr 4, ...Scorching Hot Biotech Stocks Tape: Clovis Oncology (CLVS), PTC Therapeutics (PTCT)ZergwatchShare Recap and Earnings Focus on Clovis Oncology, Inc. (NASDAQ:CLVS)Wall Street Hints and Newsall 3 news articles »
05/16/16 09:41 AMTwo Movers inside Traders Radar: Clovis Oncology, Inc. (NASDAQ:CLVS) , Insys Therapeutics, Inc. (NASDAQ:INSY) - Street Updates - Two Movers inside Traders Radar: Clovis Oncology, Inc. (NASDAQ:CLVS) , Insys Therapeutics, Inc. (NASDAQ:INSY)Street UpdatesOn 5/13/2016, shares of Clovis Oncology, Inc. (NASDAQ:CLVS) rose +2.71% in trading session and finally closed at $12.50. The company most recent volume stood at 671.08 thousand shares as compared to its average volume of 1.44 million shares.After Last Week What Do Analysts Think Of Clovis Oncology, Inc. (NASDAQ:CLVS)Share Trading Newsall 3 news articles »
About Clovis Oncology

Clovis Oncology logoClovis Oncology, Inc. (Clovis) is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company is developing three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib, an oral epidermal growth factor receptor (EGFR), is a mutant-selective covalent inhibitor that is in advanced clinical development for the treatment of non-small cell lung cancer. Rucaparib, an oral inhibitor of poly (ADP-ribose) polymerase (PARP), is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1-3 (FGFR1-3), vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/B) that is in Phase II development for the treatment of breast and lung cancers.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CLVS
  • CUSIP: 18946410
Key Metrics:
  • Previous Close: $15.06
  • 50 Day Moving Average: $14.43
  • 200 Day Moving Average: $19.33
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $578.08M
  • Current Quarter EPS Consensus Estimate: $-8.00 EPS
Additional Links:
Clovis Oncology (NASDAQ:CLVS) Chart for Thursday, June, 30, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha